S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents

Blume-Peytavi, Ulrike; Blumeyer, Anja; Tosti, Antonella; Finner, Andreas M.; Marmol, Véronique Del; Trakatelli, M.; Reygagne, P.; Messenger, A.G.

doi:10.1111/j.1365-2133.2010.10011.x

Cited by 201 publications

(206 citation statements)

References 56 publications

(124 reference statements)

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of AGA is different between populations; among asian, native american, and many men of african heritage is lower than that among caucasians with a decreased frequency of frontal hair loss and less extensive hair loss [1,2,11].…”

Section: Introductionmentioning

confidence: 94%

“…An increased activity of 5-alphareductase type II plays an important role in the development of AGA; Levels of this isoenzyme are higher in men than in women and in the areas affected by AGA [1,3].…”

Section: Pathophysiology Of Androgenetic Alopeciamentioning

confidence: 99%

“…It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women [1]. Is the most frequent type of hair loss in both sexes [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

“…The frequency and severity of this type of hair loss increases with age [5]. It usually appears in the third and fourth decades and affects 30% to 50% of men by the age of 50 and around 80% of caucasian men aged over 70 years [1,2,[6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Androgenetic Alopecia: a Review and Emerging Treatments

Alves¹

2017

CRDOA

View full text Add to dashboard Cite

Androgenetic Alopecia (AGA) is the most common noncicatricial alopecia that leads to the progressive miniaturization of the hair follicle. Scalp terminal hairs are converted into vellus hairs, primarily due to two factors: genetic predisposition and hormonal stimulation.The incidence and prevalence of AGA increases with age. The onset of AGA is gradual, and when this pathology progresses, the anagen phase shortens and the telogen phase remains constant. The shedding area varies from patient to patient and is usually most marked at the vertex in men, while women with AGA generally lose hair diffusely over the crown.Topical minoxidil and oral finasteride (5-alpha-reductase type II inhibitor) are the gold-standard therapies for AGA and are currently the only Food and Drug Administration (FDA)-approved drugs for the treatment of AGA.The currently available treatments for AGA are sometimes perceived as having limited effectiveness; therefore, the identification of new therapies for this pathology is of utmost importance.This article aims to review the pathogenesis, diagnosis of AGA and all the new emerging treatments for this entity in order to prevent its progression and improve the results of this pathology.

show abstract

Section: Introductionmentioning

confidence: 94%

Section: Pathophysiology Of Androgenetic Alopeciamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Androgenetic Alopecia: a Review and Emerging Treatments

Alves¹

2017

CRDOA

View full text Add to dashboard Cite

show abstract

“…Male patients belonging to Indian ethnicity aged above fifty years diagnosed as having androgenic alopecia [12] by a registered medical practitioner (R.M.P.) or clinician were recruited in this study.…”

Section: Inclusion Criteriamentioning

confidence: 99%

Cap Wearing and Quality of Life in Patients with Androgenic Alopecia amongst Indian Population

Abbasi¹,

Abbasi²,

Lee³

et al. 2017

J Comm Pub Health Nurs

View full text Add to dashboard Cite

Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride

et al. 2021

View full text Add to dashboard Cite

ImportanceThere is ongoing controversy about the adverse events of finasteride, a drug used in the management of alopecia and benign prostatic hyperplasia (BPH). In 2012, reports started emerging on men who had used finasteride and either attempted or completed suicide.ObjectiveTo investigate the association of suicidality (ideation, attempt, and completed suicide) and psychological adverse events (depression and anxiety) with finasteride use.Design, Setting, and ParticipantsThis pharmacovigilance case-noncase study used disproportionality analysis (case-noncase design) to detect signals of adverse reaction of interest reported with finasteride in VigiBase, the World Health Organization’s global database of individual case safety reports. To explore the strength of association, the reporting odds ratio (ROR), a surrogate measure of association used in disproportionality analysis, was used. Extensive sensitivity analyses included stratifying by indication (BPH and alopecia) and age (≤45 and >45 years); comparing finasteride signals with those of drugs with different mechanisms but used for similar indications (minoxidil for alopecia and tamsulosin hydrochloride for BPH); comparing finasteride with a drug with a similar mechanism of action and adverse event profile (dutasteride); and comparing reports of suicidality before and after 2012. Data were obtained in June 2019 and analyzed from January 25 to February 28, 2020.ExposuresReported finasteride use.Main Outcomes and MeasuresSuicidality and psychological adverse events.ResultsVigiBase contained 356 reports of suicidality and 2926 reports of psychological adverse events (total of 3282 adverse events of interest) in finasteride users (3206 male [98.9%]; 615 of 868 [70.9%] with data available aged 18-44 years). A significant disproportionality signal for suicidality (ROR, 1.63; 95% CI, 1.47-1.81) and psychological adverse events (ROR, 4.33; 95% CI, 4.17-4.49) in finasteride was identified. In sensitivity analyses, younger patients (ROR, 3.47; 95% CI, 2.90-4.15) and those with alopecia (ROR, 2.06; 95% CI, 1.81-2.34) had significant disproportionality signals for increased suicidality; such signals were not detected in older patients with BPH. Sensitivity analyses also showed that the reports of these adverse events significantly increased after 2012 (ROR, 2.13; 95% CI, 1.91-2.39).Conclusions and RelevanceIn this pharmacovigilance case-noncase study, significant RORs of suicidality and psychological adverse events were associated with finasteride use in patients younger than 45 years who used finasteride for alopecia. The sensitivity analyses suggest that these disproportional signals of adverse events may be due to stimulated reporting and/or younger patients being more vulnerable to finasteride’s adverse effects.

show abstract

S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents

Cited by 201 publications

References 56 publications

Androgenetic Alopecia: a Review and Emerging Treatments

Androgenetic Alopecia: a Review and Emerging Treatments

Cap Wearing and Quality of Life in Patients with Androgenic Alopecia amongst Indian Population

Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride

Contact Info

Product

Resources

About